ArticleFrontiers in medicine2025

Efficacy and safety of dual-targeted therapy for refractory inflammatory bowel disease: a retrospective case series from three tertiary general hospitals in China.

Xiaoying Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.